Form 4: Teva Legal Officer Exercises RSUs, Sells Shares for Tax

Teva's Interim Chief Legal Officer, Brian Savage, exercised restricted share units and sold a portion of the resulting ordinary shares to cover tax obligations.

Summary

• Brian Savage, Teva Pharmaceutical Industries Ltd.'s Interim Chief Legal Officer, acquired 3,461 ordinary shares on March 3, 2026, through the vesting of restricted share units (RSUs).
• Following this acquisition, Savage beneficially owned 4,200 ordinary shares.
• Concurrently, Savage disposed of 1,274 ordinary shares at a weighted average price of $32.3599 per share to satisfy tax withholding obligations related to the RSU vesting.
• After these transactions, Savage's direct beneficial ownership of ordinary shares stands at 2,926.
• Additionally, 3,461 restricted share units remain beneficially owned, which are scheduled to vest on March 3, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine insider transaction related to executive compensation and tax obligations, not indicative of significant positive or negative company developments.

Positives

• The vesting of restricted share units indicates the fulfillment of compensation agreements for the Interim Chief Legal Officer, aligning executive incentives with company performance.

Negatives

• The sale of 1,274 ordinary shares, even for tax withholding purposes, results in a reduction of the reporting person's direct beneficial ownership in the company.

Future Outlook

The filing indicates a future vesting event for 3,461 restricted share units on March 3, 2027, which will convert into ordinary shares or their cash equivalent at the discretion of the Human Resources and Compensation Committee.

Industry Context

StockSavvy.ai notes that this Form 4 filing represents a routine insider transaction within the pharmaceutical industry, specifically related to executive compensation. Such transactions, involving the vesting of restricted stock and subsequent sales for tax purposes, are common and generally do not reflect a change in the company's fundamental outlook or strategic direction. They are standard mechanisms for executive equity compensation.

Comparison to Industry Standards

• The practice of granting Restricted Share Units (RSUs) as part of executive compensation is a standard across the pharmaceutical and broader corporate sectors, aligning executive interests with long-term shareholder value.
• The sale of shares to cover tax withholding obligations upon RSU vesting is also a common and expected practice for executives across industries, including major pharmaceutical companies like Pfizer, Merck, and Johnson & Johnson, and does not typically signal a discretionary divestment.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned compensation event for an officer, not a discretionary sale or a significant change in ownership that would materially affect the company's stock price or governance.
• Employees: No direct impact mentioned.

Next Steps

• The remaining 3,461 restricted share units are scheduled to vest on March 3, 2027.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Brian Savage, Interim Chief Legal Officer, Restricted Share Units, RSU vesting, Insider Transaction, Form 4, Share Sale, Tax Withholding